Multipotent mesenchymal stromal cells synergize with costimulation blockade in the inhibition of immune responses and the induction of foxp3+regulatory T cells

Stem Cells Translational Medicine

Volumn 3, Issue 12, 2014, Pages 1484-1494

  Takahashi, Tohru ^a,b   Tibell, Annika ^a   Liung, Karin ^a   Saito, Yu ^a   Gronlund, Anna ^a   Osterholm, Cecilia ^a   Holgersson, Jan ^c   Lundgren, Torbjörn ^a   Ericzon, Bo Göran ^a   Corbascio, Matthias ^d   Kumagai Braesch, Makiko ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti CD40L; Costimulation blockade; CTLA4Ig; Foxp3+ regulatory T cell; Mesenchymal stem cells; Rejection

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INDOLEAMINE 2, 3 DIOXYGENASE; INSULIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4 CD25 T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GLUCOSE TOLERANCE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MESENCHYMAL STROMA CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TRANSPLANTATION; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DIABETES MELLITUS, EXPERIMENTAL; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; PANCREAS ISLET BETA CELL; PATHOLOGY;

ALLOGRAFTS; ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOGLOBULIN G; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INSULIN-SECRETING CELLS; INTERFERON-GAMMA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MULTIPOTENT STEM CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84913598305     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0012     Document Type: Article

References (35)

1. McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med 2012;2:a007823.
2. Shapiro AMJ, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosup-pressive regimen. N Engl J Med 2000;343:230–238.
3. Miller LW. Cardiovascular toxicities of im-munosuppressive agents. Am J Transplant 2002; 2:807–818.
4. Casiraghi F, Azzollini N, Cassis P et al. Pre-transplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008;181:3933–3946.
5. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allog-rafts or xenografts. Nature 1984;307:168–170.
6. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesen-chymalstemcells. Lancet 2004;363:1439–1441.
7. Le Blanc K, Frassoni F, Ball L et al. Mesenchy-mal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579–1586.
8. Le Blanc K, Mougiakakos D. Multipotent mes-enchymal stromal cells and the innate immune system. Nat Rev Immunol 2012;12:383–396.
9. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013;13:392–402.
10. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesen-chymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26:212–222.
11. Chen HW, Chen HY, Wang LT et al. Mes-enchymal stem cells tune the development of monocyte-deriveddendriticcells towardamye-loid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 2013;190:5065–5077.
12. Luz-Crawford P, Kurte M, Bravo-Alegría J et al. Mesenchymal stem cells generate a CD4 +CD25+Foxp3+ regulatoryTcell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013;4:65.
13. Engela AU, Baan CC, Litjens NH et al. Mes-enchymal stem cells control alloreactive CD8(+) CD28(2) T cells. Clin Exp Immunol 2013;174: 449–458.
14. Dahlke MH, Hoogduijn M, Eggenhofer E et al. Toward MSC in solid organ transplantation: 2008 Position paper of the MISOT Study Group. Transplantation 2009;88:614–619.
15. Kinnear G, Jones ND, Wood KJ. Costimulation blockade: Current perspectives and implications for therapy. Transplantation 2013;95:527–535.
16. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allo-grafts after blocking CD40 and CD28 pathways. Nature 1996;381:434–438.
17. Oderup C, Malm H, Ekberg H et al. Costi-mulation blockade-induced cardiac allograft tolerance: Inhibition of T cell expansion and ac-cumulationof intragraft CD4(+)Foxp3(+)T cells. Transplantation 2006;82:1493–1500.
18. Trambley J, Bingaman AW, Lin A et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999;104:1715–1722.
19. Kitchens WH, Haridas D, Wagener ME et al. Combined costimulatory and leukocyte functional antigen-1 blockade prevents transplant rejection mediated by heterologous immune memory alloresponses. Transplantation 2012;93:997–1005.
20. Kim YH, Wee YM, Choi MY et al. Interleu-kin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 2011;17: 697–708.
21. Park KS, Kim YS, Kim JH et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogen-esis of isolated islets after transplantation. Transplantation 2010;89:509–517.
22. Choi YS, Jeong JA, Lim DS. Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppres-sive effect. Immunol Invest 2012;41:214–229.
23. Takahashi T, Matsumoto S, Matsushita M et al. Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res 2010;163:e23–e34.
24. Choi EW, Shin IS, Lee HW et al. Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med 2011;13:3–16.
25. Sullivan C, Barry F, Ritter T et al. Allogeneic murine mesenchymal stem cells: Migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev 2013;22:3203–3213.
26. Ito T, Itakura S, Todorov I et al. Mesen-chymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 2010;89:1438–1445.
27. Hubo M, Trinschek B, Kryczanowsky F et al. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 2013;4:82.
28. Zhao ZG, Xu W, Sun L et al. Immunomod-ulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest 2012;41:183–198.
29. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667–679.
30. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097–1101.
31. Charpentier B. Belatacept: A novel im-munosuppressive agent for kidney transplant recipients. Expert Rev Clin Immunol 2012;8: 719–728.
32. Tan J, Wu W, Xu X et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants:A randomized controlled trial. JAMA 2012;307:1169–1177.
33. Watanabe M, Yamashita K, Suzuki T et al. ASKP1240,afully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant 2013;13:1976–1988.
34. Goldwater R, Keirns J, Blahunka P et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant 2013;13: 1040–1046.
35. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. Adv Exp Med Biol 2009;647:8–36.